V
Vianney Tricou
Researcher at Takeda Pharmaceutical Company
Publications - 38
Citations - 1545
Vianney Tricou is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Dengue vaccine & Dengue fever. The author has an hindex of 12, co-authored 30 publications receiving 1224 citations. Previous affiliations of Vianney Tricou include University of Oxford & Pasteur Institute.
Papers
More filters
Journal ArticleDOI
A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults.
Vianney Tricou,Nguyet Nguyen Minh,Toi Pham Van,Sue J. Lee,Sue J. Lee,Jeremy Farrar,Jeremy Farrar,Bridget Wills,Bridget Wills,Hien Tinh Tran,Cameron P. Simmons,Cameron P. Simmons +11 more
TL;DR: CQ does not reduce the durations of viraemia and NS1 antigenaemia in dengue patients and was associated with significantly more adverse events, primarily vomiting.
Journal ArticleDOI
Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses.
Vu Thi Ty Hang,Nguyen Minh Nguyet,Vianney Tricou,Sutee Yoksan,Nguyen Minh Dung,Tran Van Ngoc,Tran Tinh Hien,Jeremy Farrar,Bridget Wills,Cameron P. Simmons +9 more
TL;DR: Data suggest NS1 assays deserve inclusion in the diagnostic evaluation of dengue patients, but with due consideration for the limitations in patients who present late in their illness or have a concomitant humoral immune response.
Journal ArticleDOI
Kinetics of Viremia and NS1 Antigenemia Are Shaped by Immune Status and Virus Serotype in Adults with Dengue
TL;DR: The findings suggest that the early magnitude of viremia is positively associated with disease severity, and the clearance of DENV is associated with immune status, and there are serotype dependent differences in infection kinetics.
Journal ArticleDOI
Comparison of two dengue NS1 rapid tests for sensitivity, specificity and relationship to viraemia and antibody responses
Vianney Tricou,Hang T T Vu,Nhu V N Quynh,Chau V V Nguyen,Hien Tinh Tran,Jeremy Farrar,Bridget Wills,Cameron P. Simmons +7 more
TL;DR: The data suggest that the NS1 test component of these assays are highly specific and have similar levels of sensitivity, and the IgM parameter in the SD Duo test improved overall test sensitivity without compromising specificity.
Journal ArticleDOI
Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Shibadas Biswal,Charissa Borja-Tabora,Luis Vargas,Hector Velásquez,Maria Theresa Alera,Victor Sierra,Edith Johana Rodriguez-Arenales,Delia Yu,V. Pujitha Wickramasinghe,Edson D. Moreira,Asvini D. Fernando,Dulanie Gunasekera,Pope Kosalaraksa,Felix Espinoza,Eduardo López-Medina,Lulu Bravo,Suely Tuboi,Yanee Hutagalung,Pedro Garbes,Ian Escudero,Martina Rauscher,Svetlana Bizjajeva,Inge Lefevre,Astrid Borkowski,Xavier Sáez-Llorens,Derek Wallace,Alys Concepción,Ana Cecilia Villarreal,Asvini Fernando,Chukiat Sirivichayakul,Edith Johanna Rodriguez-Arenales,Humberto Reynales,Kleber Giovanni Luz,José Jimeno,LakKumar Fernando,Luis Rivera,Onanong Manacharoen,Pio Lopez,Reynaldo Dietze,Rivaldo Venâncio da Cunha,Veerachai Watanaveeradej,Manja Brose,Kelley Moss,Seetha Meyer,Vianney Tricou +44 more
TL;DR: TAK-003 was well tolerated and efficacious against symptomatic dengue in children regardless of serostatus before immunisation, warranting continued follow-up to assess longer-term vaccine performance.